Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diflomotecan in Sensitive SCLC
NCT00080015Phase 2Completed
- Sponsor
- Ipsen
- Start
- Mar 2004
- Primary completion
- Feb 2005
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, open-label, single-arm trial of diflomotecan in small cell lung cancer (SCLC), sponsored by Ipsen. Primary endpoint: Overall Objective Response Rate. Started Mar 2004; status: completed.
02
Drugs
diflomotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00080015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00080015.